Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers

Table 3 Correlation between lncRNA NNT-AS1 expression and other clinicopathological parameters for cancers

Clinicopathologic parameters	No. of Studies	No. of Participants	Pooled OR (95% CI)	P	Model	Heterogeneity
Clinicopathologic parameters	No. of Studies	No. of Participants	Pooled OR (95% CI)	P	Model	Chi², p-value, I² (%)
Age (≥50/< 50)	2	106	1.09 (0.51, 2.35)	0.82	Fixed	0.26, 0.61, 0
Age (≥60/< 60)	4	213	0.81 (0.45, 1.46)	0.49	Fixed	2.33, 0.51, 0
Gender (Male/Female)	7	470	1.03 (0.71, 1.50)	0.88	Fixed	2.85, 0.83, 0
TNM stage (III-IV/I-II)	5	255	4.25 (1.71, 10.56)	0.002	Random	8.67, 0.07, 54
LNM (Positive/Negative)	6	334	3.92 (1.35, 11.41)	0.01	Random	18.81, 0.002, 73
DM (Positive/Negative)	3	285	2.45 (1.39, 4.30)	0.002	Fixed	0.01, 0.99, 0
Vascular invasion (Positive/Negative)	2	159	3.98 (2.05, 7.71)	P < 0.0001	Fixed	0.22, 0.64, 0

CI confidence interval, DM distant metastasis, LNM lymph node metastasis, OR odds ratio, NNT-AS1 nicotinamide nucleotide transhydrogenase antisense RNA

ISSN: 1471-2407